Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
These may include frequent follow-up visits, continuous glucose monitoring for diabetes patients, regular weight checks, dietitian consultations, and participation in weight management support groups
The tools presented may include: *** The Netherlands: The 40-40-20 rule, which balances social, mid-income, and market-rate housing in new developments
Some PASC conditions (e.g., cardiovascular, hematological, and neurological) clearly overlap with known AEs linked with the COVID-19 mRNA products, such as myocarditis, stroke, or thromboembolism